Managing arthralgia in a postmenopausal woman taking an aromatase inhibitor for hormonesensitive early breast cancer: A case study

Cancer Management and Research

Volumn 4, Issue 1, 2012, Pages 105-111

  Bryce, Jane ^a   Bauer, Martina ^b   Hadji, Peyman ^b  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Adherence; Anastrozole; Aromatase inhibitor; Arthralgia; Breast cancer; Letrozole

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; CALCIUM; DICLOFENAC; ESTROGEN RECEPTOR; LETROZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PROGESTERONE RECEPTOR; VITAMIN D;

ADULT; ANAMNESIS; ARTHRALGIA; ARTICLE; BODY MASS; BONE DENSITY; BREAST CANCER; CALCIUM INTAKE; CANCER RADIOTHERAPY; CASE REPORT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FRACTURE; HUMAN; IRRITABLE COLON; JOINT STIFFNESS; MAMMOGRAPHY; MASSAGE; MUSCULOSKELETAL DISEASE; MYALGIA; PHYSIOTHERAPY; POSTMENOPAUSE; SENTINEL LYMPH NODE BIOPSY; SIDE EFFECT; STRETCHING EXERCISE; TUMOR VOLUME; VITAMIN INTAKE; YOGA;

EID: 84859540098     PISSN: None     EISSN: 11791322     Source Type: Journal    
DOI: 10.2147/CMAR.S29448     Document Type: Article

References (45)

1. Gnant M, Harbeck N, Thomssen C. St Gallen 2011: Summary of the Consensus Discussion. Breast Care (Basel). 2011;6(2):136-141.
2. Aebi S, Davidson T, Gruber G, Castiglione M, ESMO Guidelines Working Group. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010; 21(Suppl 5):v9-v14.
3. Burstein HJ, Prestrud AA, Seidenfeld J, et al; American Society of Clinical Oncology. American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol. 2010;28:3784-3796.
4. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Breast Cancer. V2.2011. Available from: http://www.nccn.org/professionals/physician_gls/f_guidelines. asp. Accessed May 1, 2011.
5. Goldhirsch A, Ingle JN, Gelber RD, et al; Panel members. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol. 2009;20(8):1319-1329.
6. Mansell J, Monypenny IJ, Skene AI, et al. Patterns and predictors of early recurrence in postmenopausal women with estrogen receptorpositive early breast cancer. Breast Cancer Res Treat. 2009;117(1): 91-98.
7. Breast International Group (BIG) 1-98 Collaborative Group, Thürlimann B, Keshaviah A, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med. 2005;353(26):2747-2757.
8. BIG 1-98 Collaborative Group, Mouridsen H, Giobbie-Hurder A, et al. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med. 2009;361(8):766-776.
9. Regan MM, Neven P, Giobbie-Hurder A, et al. Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8r1 years median follow-up. Lancet Oncol. 2011;12(12):1101-1108.
10. AstraZeneca. Secondary adjuvant long term study with arimidex (SALSA). In: ClinicalTrials. gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2000. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00295620. NLM Identifier: NCT00295620. Accessed May 1, 2011.
11. National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI); Novartis. Letrozole in treating postmenopausal women who have received hormone therapy for hormone receptor-positive breast cancer. In: ClinicalTrials. gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2000. Available from: http://www.clinicaltrials.gov/ct2/ show/NCT00382070. NLM Identifier: NCT00382070. Accessed May 1, 2011.
12. International Breast Cancer Study Group; National Cancer Institute (NCI). Letrozole in preventing cancer in postmenopausal women who have received 4-6 years of hormone therapy for hormone receptor-positive, lymph node-positive, early-stage breast cancer. In: ClinicalTrials. gov [website on Internet]. Bethesda, MD: US National Library of Medicine; 2000. Available from: http://www.clinicaltrials.gov/ct2/ show/NCT00553410. NLM Identifier: NCT00553410. Accessed May 1, 2011.
13. Hadji P. Menopausal symptoms and adjuvant therapy-associated adverse events. Endocr Relat Cancer. 2008;15(1):73-90.
14. Howell A, Cuzick J, Baum M, et al; ATAC Trialists' Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet. 2005;365(9453):60-62.
15. Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists' Group, Forbes JF, Cuzick J, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol. 2008;9(1):45-53.
16. Cuzick J, Sestak I, Baum M, et al; ATAC/LATTE investigators. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol. 2010;11(12):1135-1141.
17. Jones SE, Seynaeve C, Hasenburg A, et al. Results of the first planned analysis of the TEAM (tamoxifen exemestane adjuvant multinational) prospective randomized phase III trial in hormone sensitive postmenopausal early breast cancer. Cancer Res. 2009; 69(Suppl 2; Abstr 15):66s.
18. van de Velde CJ, Rea D, Seynaeve C, et al. Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial. Lancet. 2011;377(9762):321-331.
19. Coombes RC, Kilburn LS, Snowdon CF, et al; Intergroup Exemestane Study. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet. 2007;369(9561):559-570.
20. Coombes R, Kilburn L, Beare S, Snowdon C, Bliss J. Imperial College London, Oncology, London, United Kingdom; Institute of Cancer Research, ICR Clinical Trials and Statistics Unit (ICR-CTSU), Sutton, United Kingdom. Survival and safety post study treatment completion: an updated analysis of the Intergroup Exemestane Study (IES)-submitted on behalf of the IES Investigators. Eur J Cancer. 2009;7(Suppl 2):263, Abst O-5010.
21. Goss PE, Ingle JN, Martino S, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst. 2005;97(17):1262-1271.
22. Banning M. Adherence to adjuvant therapy in post-menopausal breast cancer patients: a review. Eur J Cancer Care (Engl). 2012;21(1):10-19.
23. Gotay C, Dunn J. Adherence to long-term adjuvant hormonal therapy for breast cancer. Expert Rev Pharmacoecon Outcomes Res. 2011;11(6):709-715.
24. Hershman DL, Shao T, Kushi LH, et al. Early discontinuation and nonadherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat. 2011;126(2):529-537.
25. Ziller V, Kalder M, Albert US, et al. Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer. Ann Oncol. 2009;20(3):431-436.
26. Partridge AH, La Fountain A, Mayer E, Taylor BS, Winer E, Asnis-Alibozek A. Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol. 2008;26(4):556-562.
27. Hadji P. Improving compliance and persistence to adjuvant tamoxifen and aromatase inhibitor therapy. Crit Rev Oncol Hematol. 2010; 73(2):156-166.
28. Dent SF, Hopkins S, DiValentin T, Verreault J, Vandermeer L, Verma S; The Ottawa Hospital Regional Cancer Centre (TOHRCC), Ottawa, ON, Canada. Adjuvant aromatase inhibitors in early breast cancer toxicity and adherence. Important observations in clinical practice. Breast Cancer Res Treat. 2007;106(Suppl 1):S111.
29. Presant CA, Bosserman L, Young T, et al. Aromatase inhibitor-associated arthralgia and/or bone pain: frequency and characterization in non-clinical trial patients. Clin Breast Cancer. 2007;7(10):775-778.
30. Makubate B, McCowan C, Dewar JA, Thompson AM. Completion of 5-years adjuvant endocrine therapy in the community. 33rd Annual San Antonio Breast Cancer Symposium; December 8-12, 2010; San Antonio, TX, USA. Abst P5-11-11.
31. Coleman RE, Bolten WW, Lansdown M, et al. Aromatase inhibitorinduced arthralgia: clinical experience and treatment recommendations. Cancer Treat Rev. 2008;34(3):275-282.
32. Columbia University. Glucosamine and chondroitin for aromatase inhibitor induced joint symptoms in women with breast cancer. In: ClinicalTrials. gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2000. Available from: http://www.clinicaltrials. gov/ct2/show/NCT00691678. NLM Identifier: NCT00691678. Accessed May 1, 2011.
33. Greenlee H, Crew KD, Shao T, et al. Phase II study of glucosamine with chondroitin on joint symptoms induced by aromatase inhibitors in breast cancer patients. 33rd Annual San Antonio Breast Cancer Symposium; December 8-12, 2010; San Antonio, TX, USA. Abst P2-13-02.
34. Prieto-Alhambra D, Javaid MK, Servitja S, et al. Vitamin D threshold to prevent aromatase inhibitor-induced arthralgia: a prospective cohort study. Breast Cancer Res Treat. 2011;125(3):869-878.
35. Stanford University; Department of Defense. Ph I/II of vitamin D on bone mineral density and markers of bone resorption. In: ClinicalTrials. gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2000. Available from: http://www.clinicaltrials.gov/ct2/ show/NCT00904423. NLM Identifier: NCT00904423. Accessed May 1, 2011.
36. University of Kansas; Novartis Pharmaceuticals BTR Group. Vitamin D3 for aromatase inhibitor induced arthralgias (VITAL). In: ClinicalTrials. gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2000. Available from: http://www.clinicaltrials.gov/ ct2/show/NCT00867217. NLM Identifier: NCT00867217. Accessed May 1, 2011.
37. Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI). Vitamin D deficiency, muscle pain, joint pain, and joint stiffness in postmenopausal women receiving letrozole for stage I-III breast cancer. In: ClinicalTrials. gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2000. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00416715. NLM Identifier: NCT00416715. Accessed May 1, 2011.
38. Crew KD, Greenlee H, Capodice J, et al. Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol. 2007;25(25):3877-3883.
39. Thorne C. Clinical management of arthralgia and bone health in women undergoing adjuvant aromatase inhibitor therapy. Curr Opin Oncol. 2007;19(Suppl 1):S19-S28.
40. Crew KD, Capodice JL, Greenlee H, et al. Randomized, blinded, sham-controlled trial of acupuncture for the management of aromatase inhibitor-associated joint symptoms in women with early-stage breast cancer. J Clin Oncol. 2010:28(7):1154-1160.
41. Dixon JM, Renshaw L, Langridge C, et al. Anastrozole and letrozole: an investigation and comparison of quality of life and tolerability. Breast Cancer Res Treat. 2011;125(3):741-749.
42. Renshaw L, McHugh M, Williams L, et al. Comparison of joint problems as reported by patients in a randomised adjuvant trial of anastrozole and letrozole. Breast Cancer Res Treat. 2007;106(Suppl 1):S108, Abst 2072.
43. Briot K, Tubiana-Hulin M, Bastit L, Kloos I, Roux C. Effect of a switch of aromatase inhibitors on musculoskeletal symptoms in postmenopausal women with hormone-receptor-positive breast cancer: the ATOLL (articular tolerance of letrozole) study. Breast Cancer Res Treat. 2010;120(1):127-134.
44. Yardley D, Green N, Papish S, et al. Rheumatologic evaluation of adjuvant letrozole in post-menopausal breast cancer patients discontinuing anastrozole due to grade 2-3 arthralgia or myalgia. Cancer Res. 2009;69(24 Suppl 3):Abst 805.
45. Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists' Group, Forbes JF, Cuzick J, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol. 2008;9(1):45-53.